For instance, tocilizumab, targeting the IL-6R, is approved for rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman disease, while sarilumab, also targeting the IL-6R, is in late-stage clinical trials [8]. The gene discussed is IL6R; the disease is Castleman disease.